In 2018, a worldwide initiative for clinical research in ataxia, the Ataxia Global Initiative (AGI) (https://ataxia-global-initiative.net), was initiated with the aim of establishing consensus on standards for clinical trials on SCA3/MJD and other ataxias, among academic institutions, industry companies and regulatory authorities. This evidence concerns the gene ATXN3 and Ataxia.